Tianeptine: A review of its use in depressive disorders

CNS Drugs

Volumn 15, Issue 3, 2001, Pages 231-259

  Wagstaff, A J ^a   Ormrod, D ^a   Spencer, C M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; FLUOXETINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ALCOHOLISM; ANXIETY NEUROSIS; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DEPENDENCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HUMAN EXPERIMENT; NONHUMAN; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TRANQUILIZING ACTIVITY;

EID: 0035067929     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200115030-00006     Document Type: Review

References (141)

1. Newer antidepressants: Beyond selective serotonin reuptake inhibitor antidepressants
2. Tianeptine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression
3. Neurochemical and pharmacological properties of tianeptine, a novel antidepressant
4. The paradox of tianeptine
5. Increased serotonin platelet uptake after tianeptine administration in depressed patients
6. Behavioural and neurochemical evidence for the decrease of brain extracellular 5-HT by the antidepressant drug tianeptine
7. In vivo studies on the enhancement of serotonin reuptake by tianeptine
8. Tianeptine stimulates uptake of 5-hydroxytryptamine in vivo in the rat brain
9. Neurochemical profile of tianeptine, a new antidepressant drug
10. Chronic treatment with tianeptine attenuates the behavioural effects induced by 5-HTP, but not the effects on hippocampal 5-HT concentrations
11. The effects of tianeptine on wet-dog shakes, fore-paw treading and a flexor reflex in rats are consistent with enhancement of 5-hydroxytryptamine uptake
12. Effects of tianeptine, sertraline and clomipramine on brain serotonin metabolism: A voltammetric approach in the rat
13. Tianeptine, a selective enhancer of serotonin uptake in rat brain
14. Effects of the antidepressant drug tianeptine on plasma and platelet serotonin concentrations in the rat
15. Effects of the antidepressant drug tianeptine on plasma and platelet serotonin of depressive patients and healthy controls
16. Effect of acute and prolonged tianeptine administration on the 5-HT transporter: Electrophysiological, biochemical and radioligand binding studies in the rat brain
17. The effect of the novel antidepressant tianeptine on the concentration of 5-hydroxytryptamine in rat hippocampal dialysates in vivo
18. Influence of the novel antidepressant tianeptine on neurochemical, neuroendocrinological, and behavioral effects of stress in rats
19. Differential effects of the novel antidepressant tianeptine on L-5-hydroxytryptophan (5-HTP)-elicited corticosterone release and body weight loss
20. Inhibition of stress-induced colonic motor alterations by tianeptine
21. Chronic stress impairs rat spatial memory on the Y maze, and this effect is blocked by tianeptine pretreatment
22. Repeated restraint stress facilitates fear conditioning independently of causing hippocampal CA3 dendritic atrophy
23. Effects of tianeptine on behavioural and neurochemical responses to immobilization stress
24. The effects of tianeptine and other antidepressants on a rat model of depression
25. The novel antidepressant, tianeptine, reduces stress-evoked stimulation of the hypothalamo-pituitary-adrenal axis
26. Effect of the antidepressant tianeptine on the activity of the hypothalamo-pituitary-adrenal axis
27. Effect of chronic treatment with the antidepressant tianeptine on the hypothalamo-pituitary-adrenal axis
28. Effect of tianeptine on neuroendocrine, enzyme and behavioral responses to restraint stress in male rats
29. Effect of tianeptine on the hypothalamic control of the corticotrophic response to stress
30. Repeated stress causes reversible impairments of spatial memory performance
31. Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress
32. Antidepressant modulation of isolation and restraint stress effects on brain chemistry and morphology
33. Prevention of stress-induced morphological and cognitive consequences
34. 3H]5-hydroxytryptamine uptake in rat brain synaptosomes: Protective effects of buspirone and tianeptine
35. Tianeptine raises dopamine and blocks stress-induced noradrenaline release in the rat frontal cortex
36. Tianeptine attenuates stress-induced morphological changes in the hippocampus
37. Effects of tianeptine on stress-induced behavioural deficits and 5-HT dependent behaviour
38. Tianeptine treatment induces regionally specific changes in monoamines
39. Tianeptine increases the extracellular concentrations of dopamine in the nucleus accumbens by a serotonin-independent mechanism
40. Increase of extracellular dopamine in the prefrontal cortex: A trait of drugs with antidepressant potential?
41. Although chemically related to amineptine, the antidepressant tianeptine is not a dopamine uptake inhibitor
42. The effect of tianeptine and sertraline in three animal models of depression
43. Pharmacological antidepressive effects and tianeptine-induced 5-HT uptake increase
44. Behavioural effects of fluoxetine and tianeptine, two antidepressants with opposite action mechanisms, in rats
45. Antidepressant effects of tianeptine, of its two enantiomers and its predominant metabolite in the learned helplessness test in rats
46. Effects of the (+) and (-) enantiomers of the antidepressant drug tianeptine on 5-HTP-induced behaviour
47. Tianeptine counteracts the anxiogenic effects of benzodiazepine withdrawal, but not those of exposure to cat odour
48. Effects of tianeptine in animal models of anxiety and on learning and memory
49. Analgesic effect of tianeptine in mice
50. Effects of tianeptine on spontaneous alternation, simple and concurrent spatial discrimination learning and on alcohol-induced alternation deficits in mice
51. A comparison between the effects of tianeptine and paroxetine on memory deficits induced by long-term ethanol consumption in mice
52. Tianeptine, a specific serotonin uptake enhancer, decreases ethanol intake in rats
53. Anxiogenic responses of rats on withdrawal from chronic ethanol treatment: Effects of tianeptine
54. Comparative pharmacodynamic studies with the novel serotonin uptake-enhancing tianeptine and -inhibiting fluvoxamine utilizing EEG mapping and psychometry
55. Changes in the prolactin response to dexfenfluramine following tianeptine treatment
56. Neuroendocrine mechanisms and the precipitation of depression by life events
57. Serotonergic mechanisms of depression
58. Glucocorticoids, transmitters and stress
59. Tianeptine, a new tricyclic antidepressant metabolized by β-oxidation of its heptanoic side chain, inhibits the mitochondrial oxidation of medium and short chain fatty acids in mice
60. Effects of tianeptine on attention, memory and psychomotor performance using neuropsychological methods in young healthy volunteers
61. Pharmacokinetic and pharmacodynamic interaction between the antidepressant tianeptine and oxazepam at steady-state
62. Effects of tianeptine on vigilance and memory in young healthy volunteers
63. A double-blind placebo-controlled investigation into the effects of tianeptine and mianserin on psychomotor performance and driving skills
64. Neuroelectrophysiologic studies in alcoholic patients, undergoing withdrawal and depressed, and treated by tianeptine
65. Lack of cardiovascular side effects of the new tricyclic antidepressant tianeptine. A double-blind, placebo-controlled study in young healthy volunteers
66. Predictors of therapeutic efficacy of tianeptine in the treatment of panic disorders
67. The efficacy and safety of tianeptine in the treatment of depressive disorder: Results of a controlled double-blind multicentre study vs. amitriptyline
68. Cardiovascular tolerance to tianeptine
69. Tianeptine and amitriptyline: Controlled double-blind trial in depressed alcoholic patients
70. Long-term administration of tianeptine in depressed patients after alcohol withdrawal
71. The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans - Influence of alcohol co-administration
72. The metabolic pathways of tianeptine, a new antidepressant, in healthy volunteers
73. Pharmacokinetic and metabolic parameters of tianeptine in healthy volunteers and in populations with risk factors
74. Metabolism of tianeptine after single and multiple dosing in man
75. Tianeptine and its main metabolite. Disposition in chronic renal failure and haemodialysis
76. Tianeptine and its main metabolite pharmacokinetics in chronic alcoholism and cirrhosis
77. Pharmacokinetics and bioavailability of tianeptine in the elderly
78. Pharmacokinetics of the antidepressant tianeptine at steady state in the elderly
79. Influence of food on tianeptine and its main metabolite kinetics
80. Identification of the enzymes involved in the primary pathways of tianeptine using human in vitro models
81. Gradually increased doses of tianeptine: Maximal tolerated dose and linearity of the pharmacokinetics
82. Development of a population pharmacokinetic database for tianeptine
83. Predictive performance of pre-marketing tianeptine pharmacokinetic parameters as applied to post-marketing data
84. Episodes of severe depression in subjects over 70 years of age. Efficacy and acceptability of tianeptine and mianserine
85. A double-blind comparison of tianeptine, imipramine and placebo in the treatment of major depressive episodes
86. Placebo-controlled study of tianeptine in major depressive episodes
87. Clinically relevant effect sizes in depression
88. Can a serotonin uptake agonist be an authentic antidepressant? Results of a multicenter, multinational therapeutic trial
89. Efficacy of tianeptine in anxiousdepressed patients: Results of a controlled multicenter trial versus amitriptyline
90. Tianeptine versus dosulepine in the treatment of acute depressive disorders. A controlled study
91. Tianeptine versus dosulepine in the treatment of acute depressive disorders. A controlled study
92. Anxio-depressive disorders in menopausal and pre-menopausal women. Double blind study of tianeptine versus maprotiline
93. Controlled comparison of tianeptine, alprazolam and mianserin in the treatment of adjustment disorders with anxiety and depression
94. Suboptimal use of antidepressants in the treatment of depression
95. Mixed anxiety and depression: Diagnosis and treatment options
96. Efficacy of tianeptine (Stablon™) for the treatment of major depression and dysthymia with somatic complaints. A comparative study versus fluoxetine (Prozac™)
97. Tianeptine for the treatment of major depressive episode: A double-blind study versus fluoxetine
98. Study of the efficacy of fluoxetine versus tianeptine in the treatment of elderly depressed patients followed in general practice
99. Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine
100. Efficacy and safety of tianeptine in major depression: Evidence from a 3-month controlled clinical trial versus paroxetine
101. Efficacy and acceptability of tianeptine and sertraline in acute treatment phase of depression
102. Long-term use of tianeptine in 380 depressed patients
103. Analysis of the side effects of tianeptine
104. Efficacy of tianeptine vs placebo in the long-term treatment (16.5 months) of unipolar major recurrent depression
105. Methodological approaches to the long-term study of antidepressants
106. Efficacy and acceptability of tianeptine in the elderly: A review of clinical trials
107. The importance and need to prolong antidepressant treatment after the resolution of depression in elderly patients
108. Tianeptine and depression in 140 elderly patients treated for 1 year
109. Clinical safety and efficacy of tianeptine in 1,858 depressed patients treated in general practice
110. Depression and sexual disorders
111. Acute mixed hepatitis caused by tianeptine
112. Tianeptine - An instance of drug-induced hepatotoxicity predicted by prospective experimental studies
113. Acute painful and febrile hepatic involvement related to ingestion of tianeptine
114. Tianeptine in episodes of major depression with melancholia and signs of endogenicity
115. Abuse of tianeptine. A case report
116. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: Depression and its treatment
117. Lifetime risk of depression
118. Development of new antidepressants
119. Treatment of depression in patients with heart disease
120. Contemporary management of depression
121. SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients
122. ASHP therapeutic position statement on the recognition and treatment of depression in older adults
123. Gender differences in depression and antidepressant pharmacokinetics and adverse events
124. The prophylactic efficacy of fluoxetine in unipolar depression
125. Five-year outcome for maintenance therapies in recurrent depression
126. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression
127. Sertraline in the prevention of depression
128. Anxiety with depression: A treatment need
129. Does stress damage the brain?
130. Practical considerations for the treatment of depression in elderly and very elderly long-term care patients
131. Role of drug therapies in the treatment of alcoholism: Alcohol and anxiety - Alcohol and depression
132. Best clinical practice: Guidelines for managing major depression in primary medical care
133. Consensus statement on the primary care management of depression from the International Consensus Group on Depression and Anxiety
134. Which patients receive antidepressants? A 'real world' telephone study